• 5 min read
• Published on 25 July 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Hope & Optimism Portfolio
Let’s be honest, most of the stock market is a rather dull affair. We spend our days poring over earnings reports from companies that make slightly better widgets or sell slightly more coffee than they did last quarter. It’s a necessary game, but it hardly gets the blood pumping. Every now and then, however, I like to peek into the laboratory, the place where the real madness is happening. I’m talking about the companies that aren’t just trying to win the game, they’re trying to build a whole new one.
Investing in these ventures is, to put it mildly, a high-wire act without a safety net. But for those with a bit of nerve, it’s also where the most profound stories of progress, and potentially profit, are being written. It’s about betting on human ingenuity itself, which is perhaps the riskiest asset of all.
View the full Basket:Hope & Optimism Portfolio
For decades, medicine has been about managing symptoms. We’ve become very good at it. But a new breed of company is aiming for something far more audacious, a cure. Take the field of gene editing. It sounds like something from a science fiction novel, and until recently, it was. Now, firms like Beam Therapeutics and Editas Medicine are working on technologies that could, in theory, edit diseases right out of our DNA.
One approach works like a pencil and eraser, correcting faulty genetic code rather than just snipping it out with molecular scissors. The potential is staggering. We’re talking about a future where hereditary blindness or incurable blood disorders might be fixed with a single treatment. The rewards for the company that cracks this could be astronomical. Of course, the path is littered with failed clinical trials, regulatory black holes, and the very real possibility that it all comes to nothing. For every potential miracle, there are a dozen expensive dead ends.
View the full Basket:Hope & Optimism Portfolio
The same dynamic is playing out in the energy sector. While everyone is rightly focused on solar panels and wind turbines, there’s a glaring problem. What happens when the sun isn’t shining and the wind isn’t blowing? A few brave souls think the answer lies in reinventing nuclear power. Companies like Oklo are developing tiny, advanced fission reactors that could power a small town or an industrial park.
It’s a brilliant idea on paper. Clean, reliable, baseload power without the gargantuan cooling towers and public relations nightmares of old. But let’s be realistic. The word ‘nuclear’ still makes people nervous, and regulators are, quite rightly, the most cautious people on the planet. Getting one of these designs approved and built could take an eternity and a mountain of cash. It’s a bold vision, but one that requires an almost fanatical level of patience from an investor.
View the full Basket:Hope & Optimism Portfolio
This is the crux of it. You don’t bet the house on a single roll of the dice. To me, that’s not investing, it’s just a trip to the casino. If you’re going to wade into these waters, you need to spread your bets. You’re not looking for one company to succeed, you’re hoping that out of a dozen ambitious projects, one or two might actually change the world.
The winners in this space tend to win so spectacularly that they can make up for all the others that quietly fizzle out. This is why a diversified approach makes sense. A collection of these high-stakes ventures, like The Hope & Optimism Portfolio, allows you to back the entire scientific frontier, not just one specific expedition. It turns a series of wild punts into a more calculated, albeit still very risky, strategy. It’s an admission that you don’t know which idea will triumph, but you have a strong suspicion that one of them will.
View the full Basket:Hope & Optimism Portfolio
View the full Basket:Hope & Optimism Portfolio
View the full Basket:Hope & Optimism Portfolio
View the full Basket:Hope & Optimism Portfolio
View the full Basket:Hope & Optimism Portfolio
View the full Basket:Hope & Optimism Portfolio
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article